Patient characteristics and outcome
| Characteristic . | No. (%)* . | % PFS at 62 mo† . | P2‡ . | % OS at 62 mo† . | P2‡ . |
|---|---|---|---|---|---|
| Total patients | 50 (100) | 70 | 73 | ||
| Sex | |||||
| Male | 25 (50) | 71 | .92 | 75 | .83 |
| Female | 25 (50) | 68 | 71 | ||
| Median age, y (range) | 46 (20-88) | ||||
| Younger than or equal to 60 y | 38 (76) | 68 | .85 | 78 | .14 |
| Older than 60 y | 12 (24) | 73 | 58 | ||
| Performance status | |||||
| ECOG 0 to 1 | 45 (90) | 68 | .59 | 70 | .19 |
| ECOG at least 2 | 5 (10) | 80 | 100 | ||
| Disease stage | |||||
| I/II | 6/7 (26) | 85 | .47 | 85 | .39 |
| III/IV | 9/28 (74) | 64 | 69 | ||
| LDH level | |||||
| Normal | 15 (30) | 80 | .40 | 86 | .18 |
| Above normal | 35 (70) | 65 | 68 | ||
| Extranodal sites | |||||
| 0 to 1 | 33 (66) | 78 | .07 | 81 | .09 |
| At least 2 | 17 (34) | 53 | 58 | ||
| IPI score | |||||
| Low (0-1) | 19 (38) | 79 | .52 | 84 | 2-153 |
| Low intermediate (2) | 9 (18) | 78 | 100 | ||
| High intermediate (3) | 16 (32) | 54 | 42 | ||
| High (4-5) | 6 (12) | 67 | 83 | ||
| Age-adjusted IPI score | |||||
| Low (0) | 4 (8) | 100 | .50 | 100 | .10 |
| Low intermediate (1) | 20 (40) | 75 | 80 | ||
| High intermediate (2) | 21 (42) | 56 | 55 | ||
| High (3) | 5 (10) | 80 | 100 | ||
| Bcl-2 status (n = 29) | |||||
| Negative | 17 (59) | 82 | .04 | 82 | .37 |
| Positive | 12 (41) | 50 | 67 | ||
| MIB-1 status (n = 33) | |||||
| At least 80% | 19 (58) | 74 | .24 | 79 | .35 |
| Less than 80% | 14 (42) | 62 | 64 | ||
| P53 status (n = 33) | |||||
| Negative | 25 (76) | 72 | .17 | 80 | .04 |
| Positive | 8 (24) | 60 | 50 |
| Characteristic . | No. (%)* . | % PFS at 62 mo† . | P2‡ . | % OS at 62 mo† . | P2‡ . |
|---|---|---|---|---|---|
| Total patients | 50 (100) | 70 | 73 | ||
| Sex | |||||
| Male | 25 (50) | 71 | .92 | 75 | .83 |
| Female | 25 (50) | 68 | 71 | ||
| Median age, y (range) | 46 (20-88) | ||||
| Younger than or equal to 60 y | 38 (76) | 68 | .85 | 78 | .14 |
| Older than 60 y | 12 (24) | 73 | 58 | ||
| Performance status | |||||
| ECOG 0 to 1 | 45 (90) | 68 | .59 | 70 | .19 |
| ECOG at least 2 | 5 (10) | 80 | 100 | ||
| Disease stage | |||||
| I/II | 6/7 (26) | 85 | .47 | 85 | .39 |
| III/IV | 9/28 (74) | 64 | 69 | ||
| LDH level | |||||
| Normal | 15 (30) | 80 | .40 | 86 | .18 |
| Above normal | 35 (70) | 65 | 68 | ||
| Extranodal sites | |||||
| 0 to 1 | 33 (66) | 78 | .07 | 81 | .09 |
| At least 2 | 17 (34) | 53 | 58 | ||
| IPI score | |||||
| Low (0-1) | 19 (38) | 79 | .52 | 84 | 2-153 |
| Low intermediate (2) | 9 (18) | 78 | 100 | ||
| High intermediate (3) | 16 (32) | 54 | 42 | ||
| High (4-5) | 6 (12) | 67 | 83 | ||
| Age-adjusted IPI score | |||||
| Low (0) | 4 (8) | 100 | .50 | 100 | .10 |
| Low intermediate (1) | 20 (40) | 75 | 80 | ||
| High intermediate (2) | 21 (42) | 56 | 55 | ||
| High (3) | 5 (10) | 80 | 100 | ||
| Bcl-2 status (n = 29) | |||||
| Negative | 17 (59) | 82 | .04 | 82 | .37 |
| Positive | 12 (41) | 50 | 67 | ||
| MIB-1 status (n = 33) | |||||
| At least 80% | 19 (58) | 74 | .24 | 79 | .35 |
| Less than 80% | 14 (42) | 62 | 64 | ||
| P53 status (n = 33) | |||||
| Negative | 25 (76) | 72 | .17 | 80 | .04 |
| Positive | 8 (24) | 60 | 50 |
PFS indicates progression-free survival; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; LDH, lactic acid dehydrogenase; and IPI, International Prognostic Index.
Values are numbers (%) unless otherwise indicated.
Kaplan-Meier estimates at median follow-up time of 62 months.
P2 derived from log-rank test of Kaplan-Meier curves.
The inverse order of the curves within the low-risk and high-risk categories indicates that the significant difference observed (P2 = .009) does not accurately reflect the expected association of the IPI with survival.